Skip to main content
2024 AABB Annual Meeting Main banner
Icon Legend
This session is not in your favorites.
This session is in your favorites. Click again to remove it.
Presentation Icons
Live Stream Sessions
Live Stream Sessions
Video

The AABB Cellular Starting Material Forum: From Consent to Characterization - Enhancing Allogeneic Donor Practices

Monday, October 21, 2024
9:30 AM - 11:00 AM  
Location: 342
CE: 0 CME (AMA Physician Credit) / 1.5 CE (Non-Physician Credit)

    Program Chair(s)

  • Jeff Wren

    Vice President of Biotherapies
    AABB
    Minneapolis, Minnesota, United States

    Disclosure(s): No financial relationships to disclose

    • Speaker(s)

  • Priya Baraniak, PhD (she/her/hers)

    Chief Business Officer
    OrganaBio
    West Chester, Pennsylvania, United States

    Disclosure(s): OrganaBio: Full-time/Part-time Employee or Owner (Ongoing), Stock Shareholder (self-managed) (Ongoing); RoosterBio: Stock Shareholder (self-managed) (Ongoing)

  • Colleen Delaney, MD, MSc (she/her/hers)

    Founder and Chief Scientific Officer
    Deverra Therapeutics
    seattle, Washington, United States

    Disclosure(s): Coeptis Therapeutics: Full-time/Part-time Employee or Owner (Ongoing); Deverra Therapeutics: Full-time/Part-time Employee or Owner (Ongoing), Stock Shareholder (self-managed) (Ongoing)

  • Diana Hernandez, BSc PhD (she/her/hers)

    Director of Immune and Advanced Therapies
    Anthony Nolan Research Institute
    London, England, United Kingdom

    Disclosure(s): No financial relationships to disclose

  • Heather Munoz, MN, RN, CPN, CPHON, QIA (she/her/hers)

    Director
    Apheresis Operations
    Sana Biotechnology
    SEATTLE, Washington, United States

    Disclosure(s): Sana Biotechnology: Full-time/Part-time Employee or Owner (Ongoing)

  • RT

    Robert Tressler, MS, PhD

    Chief Scientific Officer
    Excellos
    SAN DIEGO, California, United States

    Disclosure(s): Excellos: Full-time/Part-time Employee or Owner (Ongoing)

Disclosure(s):
Jeff Wren: No financial relationships to disclose
Priya Baraniak, PhD: OrganaBio: Full-time/Part-time Employee or Owner (Ongoing), Stock Shareholder (self-managed) (Ongoing); RoosterBio: Stock Shareholder (self-managed) (Ongoing)
Colleen Delaney, MD, MSc: Coeptis Therapeutics: Full-time/Part-time Employee or Owner (Ongoing); Deverra Therapeutics: Full-time/Part-time Employee or Owner (Ongoing), Stock Shareholder (self-managed) (Ongoing)
Diana Hernandez, BSc PhD: No financial relationships to disclose
Heather P. Munoz, MN, RN, CPN, CPHON, QIA: Sana Biotechnology: Full-time/Part-time Employee or Owner (Ongoing)
Robert Tressler, MS, PhD: Excellos: Full-time/Part-time Employee or Owner (Ongoing)

This session will delve into the critical elements of managing allogeneic cellular starting material for biotherapies. Our expert panel, including starting material providers and allogeneic therapy developers, will explore key topics such as ensuring appropriate consent from healthy adult and cord blood donors, the impacts of genetic screening and immune profiling, and the integration of new characterization assays to enhance the quality and safety of biotherapeutic products.

This forum promises to offer valuable insights into the latest best practices and cutting-edge approaches in the field. Don’t miss this opportunity to join and participate in the discussion.